BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 32065787)

  • 21. Next-generation sequencing identified somatic alterations that may underlie the etiology of Chinese papillary thyroid carcinoma.
    Yang C; Gong J; Xu W; Liu Z; Cui D
    Eur J Cancer Prev; 2023 May; 32(3):264-274. PubMed ID: 31724970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of DNMT3A alterations in Middle Eastern papillary thyroid carcinoma.
    Siraj AK; Pratheeshkumar P; Parvathareddy SK; Bu R; Masoodi T; Iqbal K; Al-Rasheed M; Al-Dayel F; Al-Sobhi SS; Alzahrani AS; Al-Dawish M; Al-Kuraya KS
    Eur J Cancer; 2019 Aug; 117():133-144. PubMed ID: 31280122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive transcriptomic analysis of papillary thyroid cancer: potential biomarkers associated with tumor progression.
    Hosseinkhan N; Honardoost M; Blighe K; Moore CBT; Khamseh ME
    J Endocrinol Invest; 2020 Jul; 43(7):911-923. PubMed ID: 31965517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel RNA sequencing-based risk score model to predict papillary thyroid carcinoma recurrence.
    He J; Tian Z; Yao X; Yao B; Liu Y; Yang J
    Clin Exp Metastasis; 2020 Apr; 37(2):257-267. PubMed ID: 31792675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genome-wide scanning for CHD1L gene in papillary thyroid carcinoma complicated with type 2 diabetes mellitus.
    Kang YY; Li JJ; Sun JX; Wei JX; Ding C; Shi CL; Wu G; Li K; Ma YF; Sun Y; Qiao H
    Clin Transl Oncol; 2021 Dec; 23(12):2536-2547. PubMed ID: 34245428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.
    Guo M; Chen Z; Li Y; Li S; Shen F; Gan X; Feng J; Cai W; Liu Q; Xu B
    Front Endocrinol (Lausanne); 2021; 12():674616. PubMed ID: 34248843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.
    Demeure MJ; Aziz M; Rosenberg R; Gurley SD; Bussey KJ; Carpten JD
    World J Surg; 2014 Jun; 38(6):1296-305. PubMed ID: 24633422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Next-generation sequencing identified that RET variation associates with lymph node metastasis and the immune microenvironment in thyroid papillary carcinoma.
    Huang Y; Lin P; Liao J; Liang F; Han P; Fu S; Jiang Y; Yang Z; Tan N; Huang J; Chen R; Ouyang N; Huang X
    BMC Endocr Disord; 2024 May; 24(1):68. PubMed ID: 38734621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of differentiated functional modules in papillary thyroid carcinoma by analyzing differential networks.
    Yang C; Wang Y
    J Cancer Res Ther; 2018 Dec; 14(Supplement):S969-S974. PubMed ID: 30539831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrated analysis of tumor microenvironment features to establish a diagnostic model for papillary thyroid cancer using bulk and single-cell RNA sequencing technology.
    Wang Y; Song W; Li Y; Liu Z; Zhao K; Jia L; Wang X; Jiang R; Tian Y; He X
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16837-16850. PubMed ID: 37733241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Papillary thyroid carcinoma behavior: clues in the tumor microenvironment.
    Bergdorf K; Ferguson DC; Mehrad M; Ely K; Stricker T; Weiss VL
    Endocr Relat Cancer; 2019 Jun; 26(6):601-614. PubMed ID: 30965283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular characterization of tumors meeting diagnostic criteria for the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).
    Pool C; Walter V; Bann D; Goldenberg D; Broach J; Hennessy M; Cottrill E; Washburn E; Williams N; Crist H; Imamura Y; Warrick JI
    Virchows Arch; 2019 Mar; 474(3):341-351. PubMed ID: 30645670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomic and transcriptomic analyses of thyroid cancers identify DICER1 somatic mutations in adult follicular-patterned RAS-like tumors.
    Minna E; Devecchi A; Pistore F; Paolini B; Mauro G; Penso DA; Pagliardini S; Busico A; Pruneri G; De Cecco L; Borrello MG; Sensi M; Greco A
    Front Endocrinol (Lausanne); 2023; 14():1267499. PubMed ID: 37867524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma.
    Lu Z; Zhang Y; Feng D; Sheng J; Yang W; Liu B
    Oncotarget; 2017 Jul; 8(28):45784-45792. PubMed ID: 28507274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Shifting patterns of genomic variation in the somatic evolution of papillary thyroid carcinoma.
    Rubinstein JC; Brown TC; Christison-Lagay ER; Zhang Y; Kunstman JW; Juhlin CC; Nelson-Williams C; Goh G; Quinn CE; Callender GG; Udelsman R; Lifton RP; Korah R; Carling T
    BMC Cancer; 2016 Aug; 16():646. PubMed ID: 27538953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Whole exome sequencing identifies lncRNA GAS8-AS1 and LPAR4 as novel papillary thyroid carcinoma driver alternations.
    Pan W; Zhou L; Ge M; Zhang B; Yang X; Xiong X; Fu G; Zhang J; Nie X; Li H; Tang X; Wei J; Shao M; Zheng J; Yuan Q; Tan W; Wu C; Yang M; Lin D
    Hum Mol Genet; 2016 May; 25(9):1875-84. PubMed ID: 26941397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identifying the tumor-progressive gene expression profile in high-risk papillary thyroid cancer.
    Shibata M; Inaishi T; Ichikawa T; Shimizu D; Soeda I; Takano Y; Takeuchi D; Tsunoda N; Kikumori T
    Surg Today; 2021 Oct; 51(10):1703-1712. PubMed ID: 33733290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Copy Number Alterations in Papillary Thyroid Carcinomas: Does Loss of
    DE Almeida DCN; DE Souza MPC; Amorim CKN; DA Silva MauÉs JH; DO E Santo Sagica F; Moreira-Nunes CA; DE Oliveira EHC
    Cancer Genomics Proteomics; 2020; 17(5):643-648. PubMed ID: 32859642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BCL2 and hsa-miR-181a-5p are potential biomarkers associated with papillary thyroid cancer based on bioinformatics analysis.
    Zhang C; Bo C; Guo L; Yu P; Miao S; Gu X
    World J Surg Oncol; 2019 Dec; 17(1):221. PubMed ID: 31842912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
    Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
    Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.